In Re: Restasis Antitrust Litigation, MDL No. 2819 (E.D.N.Y.).
Lieff Cabraser serves as interim co-lead counsel for indirect purchasers (i.e., third-party payors and consumers) of Restasis, a blockbuster drug used to treat dry-eye disease, in multidistrict litigation alleging a broad-based and ongoing anticompetitive scheme by pharmaceutical giant Allergan, Inc. (“Allergan”).
In late 2018, plaintiffs successfully defeated defendants’ motion to dismiss the case. In May of 2020, the Court granted plaintiffs’ class certification motion and plaintiffs’ motion to exclude two of the defendants’ experts. The Second Circuit Court denied defendants’ appeal, and the litigation is ongoing.
Background on the Case
The goal of the alleged scheme was and is to maintain Allergan’s monopoly. Lieff Cabraser, together with co-counsel, filed the first two class actions on behalf of indirect purchasers.
The complaints allege that Allergan (1) fraudulently procured patents it knew were invalid, (2) caused those invalid patents to be listed in the FDA’s “Orange Book” as being applicable to Restasis, (3) used the improper Orange Book listings as grounds for filing baseless patent-infringement litigation, (4) abused the FDA’s “citizen petition” process, and (5) used a “sham” transfer of the invalid patents to the Saint Regis Mohawk Tribe to obtain tribal sovereign immunity and protect the patents from challenge.
This alleged scheme of government petitioning delayed competition from generic equivalents to Restasis that would have been just as safe and cheaper for consumers. The complaints assert claims under federal and state law, including the Sherman Act and the statutory and common law of numerous states.